Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own0.90% Shs Outstand160.34M Perf Week0.75%
Market Cap10.32B Forward P/E- EPS next Y-0.40 Insider Trans-10.96% Shs Float159.43M Perf Month-6.94%
Income-124.30M PEG- EPS next Q-0.39 Inst Own- Short Float5.59% Perf Quarter-8.23%
Sales709.30M P/S14.55 EPS this Y-61.10% Inst Trans-0.38% Short Ratio10.93 Perf Half Y21.29%
Book/sh8.18 P/B7.87 EPS next Y66.10% ROA-8.00% Target Price79.46 Perf Year12.30%
Cash/sh2.61 P/C24.68 EPS next 5Y23.00% ROE-9.30% 52W Range50.71 - 84.37 Perf YTD13.63%
Dividend- P/FCF- EPS past 5Y-22.40% ROI-18.60% 52W High-23.69% Beta2.24
Dividend %- Quick Ratio2.90 Sales past 5Y19.40% Gross Margin88.30% 52W Low26.96% ATR2.52
Employees1302 Current Ratio3.30 Sales Q/Q38.80% Oper. Margin-31.00% RSI (14)36.27 Volatility3.06% 3.38%
OptionableYes Debt/Eq0.00 EPS Q/Q88.70% Profit Margin-17.50% Rel Volume0.55 Prev Close66.42
ShortableYes LT Debt/Eq0.00 EarningsApr 25 AMC Payout- Avg Volume816.00K Price64.38
Recom2.30 SMA20-4.62% SMA50-10.24% SMA200-7.28% Volume476,219 Change-3.07%
Apr-11-19Initiated Stifel Hold $70
Mar-27-19Initiated Berenberg Buy $95
Oct-26-18Reiterated Barclays Overweight $95 → $90
Oct-26-18Downgrade BofA/Merrill Neutral → Underperform
Sep-25-18Initiated Leerink Partners Outperform
Sep-07-18Resumed Piper Jaffray Neutral
Jul-30-18Reiterated Needham Buy $74 → $79
Jul-27-18Reiterated H.C. Wainwright Buy $77 → $98
Jun-11-18Upgrade SunTrust Hold → Buy
Mar-20-18Resumed Barclays Overweight $74
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Feb-07-18Reiterated Needham Buy $72 → $74
Nov-13-17Reiterated RBC Capital Mkts Outperform $68 → $69
Oct-27-17Upgrade BofA/Merrill Underperform → Neutral
Oct-24-17Resumed Guggenheim Buy $72
Oct-20-17Upgrade Barclays Equal Weight → Overweight $60 → $70
Oct-06-17Resumed Goldman Neutral
Sep-15-17Initiated RBC Capital Mkts Outperform $58
Mar-16-17Initiated Oppenheimer Perform
Feb-10-17Downgrade BofA/Merrill Neutral → Underperform
May-15-19 05:10PM  Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
03:36PM  Seattle Genetics, Inc. (NASDAQ:SGEN): Financial Strength Analysis Simply Wall St.
08:00AM  Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference Business Wire
May-03-19 12:09PM  Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada Business Wire
May-01-19 04:47AM  Edited Transcript of SGEN earnings conference call or presentation 25-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
03:53PM  Seattle Genetics' "Growth Is Tracking Well" Motley Fool
Apr-26-19 01:11PM  Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark Zacks
10:48AM  SEATTLE GENETICS INC (SGEN) Q1 2019 Earnings Call Transcript Motley Fool
08:02AM  The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug Benzinga
Apr-25-19 04:08PM  Seattle Genetics: 1Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports First Quarter 2019 Financial Results Business Wire
07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
02:30AM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Apr-18-19 07:22PM  Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)? Insider Monkey
10:33AM  Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-11-19 02:48PM  Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified? Simply Wall St.
09:53AM  Seattle Genetics' Adcetris Progresses Well Amid Competition Zacks
Apr-10-19 01:40PM  5 Oncology Companies That Are Set to Run GuruFocus.com
Apr-08-19 08:45AM  Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher Zacks
Apr-04-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019 Business Wire
Apr-01-19 10:49AM  Seattle Genetics Closes Enrollment in Cervical Cancer Study Zacks
Mar-29-19 01:57PM  Seattle Genetics, Astellas Report Positive Cancer Study Data Zacks
08:00AM  Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer Business Wire
Mar-28-19 04:31PM  This Biotech Stock Toppled Despite Success In Bladder Cancer Study Investor's Business Daily
07:00AM  Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin Business Wire
03:01AM  Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Mar-27-19 08:00AM  Seattle Genetics Highlights Antibody-Drug Conjugate Innovation and Immuno-Oncology Program at the American Association for Cancer Research (AACR) Annual Meeting Business Wire
Mar-09-19 09:31AM  Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-06-19 12:22PM  ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates GuruFocus.com
06:42AM  Pullback Strategies: 10 Stocks That Could Fall the Fastest Investopedia
Mar-05-19 11:32AM  Seattle Genetics, Inc. (NASDAQ:SGEN): Are Analysts Optimistic? Simply Wall St.
08:00AM  Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference Business Wire
Mar-04-19 09:46PM  Seattle Genetics' new Bothell campus sells for $63M American City Business Journals
Feb-14-19 10:38AM  Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored Bloomberg
Feb-13-19 03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
07:35AM  New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-12-19 09:29PM  Edited Transcript of SGEN earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
05:30PM  Seattle Genetics' Adcetris Gets EC Nod for Label Expansion Zacks
Feb-11-19 08:00AM  Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma Business Wire
Feb-08-19 04:58PM  Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today Motley Fool -11.84%
04:14PM  Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'? Investor's Business Daily
03:58PM  Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark Zacks
03:24PM  Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed Motley Fool
01:17PM  Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
09:17AM  The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga
Feb-07-19 05:55PM  Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:00PM  Seattle Genetics: 4Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
11:54AM  Stocks Moving After Hours: Mattel, Skechers, Columbia Sports Investing.com
Feb-06-19 08:00AM  Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day Business Wire
Feb-04-19 09:09AM  What's in the Cards for Glaxo (GSK) This Earnings Season? Zacks
08:58AM  Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store? Zacks
Jan-31-19 10:31AM  Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Jan-22-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019 Business Wire
Jan-16-19 08:01AM  Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Have Been Selling Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-09-19 08:00AM  Seattle Genetics Announces Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma Business Wire
Jan-02-19 08:54AM  Seattle Genetics-occupied Bothell property fetches $34 million American City Business Journals
Dec-21-18 12:50AM  Hedge Funds Are Dumping Seattle Genetics, Inc. (SGEN) Insider Monkey
Dec-19-18 08:00AM  Seattle Genetics to Present at the J.P. Morgan Healthcare Conference Business Wire
Dec-10-18 07:45AM  Report: Developing Opportunities within Covanta Holding, Zscaler, Avaya, Seattle Genetics, Viad, and Canada Goose Future Expectations, Projections Moving into 2019 GlobeNewswire
Dec-03-18 09:15PM  Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas Business Wire
Dec-02-18 12:00PM  Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting Business Wire
Dec-01-18 12:00PM  Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting Business Wire
Nov-30-18 02:08PM  Seattle Genetics opening Bay Area office to attract talent it can't lure to Bothell American City Business Journals
Nov-26-18 08:00AM  Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting Business Wire
Nov-20-18 11:23AM  What You Must Know About Seattle Genetics Incs (NASDAQ:SGEN) Financial Health Simply Wall St.
Nov-19-18 08:41AM  Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session Zacks
06:55AM  Today's Research Reports on Trending Tickers: Amarin and Seattle Genetics ACCESSWIRE
Nov-16-18 01:53PM  Seattle Genetics stock jumps 6% after new FDA approval for lymphoma treatment MarketWatch +5.59%
10:52AM  Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas Business Wire
07:59AM  Seattle Genetics' Adcetris Gets Breakthrough Therapy Status Zacks
Nov-15-18 08:00AM  FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas Business Wire
Nov-14-18 08:00AM  Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma Business Wire
Nov-08-18 07:05AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Seattle Genetics ACCESSWIRE
Nov-06-18 08:00AM  Seattle Genetics to Present at the Credit Suisse 27th Annual Healthcare Conference Business Wire
Nov-05-18 08:00AM  Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas Business Wire
Nov-02-18 10:16PM  Edited Transcript of SGEN earnings conference call or presentation 25-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
05:51PM  Microsoft and Seattle Genetics buildings are part of a big Bothell sale American City Business Journals
Nov-01-18 04:05PM  Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program Business Wire
Oct-31-18 07:50AM  New Research: Key Drivers of Growth for Covanta Holding, Seattle Genetics, DSW, Canada Goose, Oaktree Capital Group, and Arthur J. Gallagher Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-30-18 02:50PM  Seattle Genetics: "Now the Hard Work Begins" Motley Fool
Oct-26-18 12:39PM  Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark Zacks -15.38%
12:29PM  Here's Why Seattle Genetics Plummeted Today Motley Fool
08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga
01:11AM  Seattle Genetics Inc (SGEN) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-25-18 04:58PM  Seattle Genetics: 3Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports Third Quarter 2018 Financial Results Business Wire
Oct-23-18 06:22AM  Seattle Genetics Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-08-18 06:50PM  Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress Business Wire
Oct-03-18 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018 Business Wire
07:50AM  Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-01-18 06:45AM  Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma Business Wire +5.24%
Sep-21-18 10:48AM  Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma Business Wire
Sep-19-18 03:18PM  Why Seattle Genetics Inc (NASDAQ:SGEN) Is A Financially Healthy Company Simply Wall St.
Sep-17-18 05:26PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
Sep-04-18 08:00AM  Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-14-18 10:55AM  Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit Zacks
01:44AM  (UMRX) Q2 2018 Earnings Conference Call Transcript Motley Fool
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident and CEOMay 09Option Exercise12.164,82458,660752,063May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 09Sale67.434,824325,301749,169May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.1615,324186,340762,600May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Sale68.2615,3241,046,066749,169May 10 04:39 PM
BAKER BROS. ADVISORS LPDirectorApr 29Option Exercise8.3820,000167,60045,839,686May 01 04:59 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.1620,148245,000757,976Apr 10 04:39 PM
SIEGALL CLAY BPresident and CEOApr 08Sale79.2220,1481,596,100749,169Apr 10 04:39 PM
SIMPSON TODD EChief Financial OfficerApr 05Sale78.0012,500975,000171,780Apr 09 08:35 PM
GRYSKA DAVID WDirectorApr 01Option Exercise12.765,00063,80050,050Apr 03 08:57 PM
GRYSKA DAVID WDirectorApr 01Sale73.415,000367,03045,050Apr 03 08:57 PM
SIEGALL CLAY BPresident and CEOMar 18Option Exercise12.0816,556199,988749,169Mar 20 06:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Option Exercise12.008,00096,000185,329Mar 12 07:31 PM
SIEGALL CLAY BPresident and CEOMar 08Option Exercise12.1620,148245,000745,259Mar 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Sale68.728,000549,746177,329Mar 12 07:31 PM
SIEGALL CLAY BPresident and CEOMar 08Sale69.1920,1481,394,094732,613Mar 12 07:34 PM
SIMPSON TODD EChief Financial OfficerMar 04Sale75.0010,000750,000184,280Mar 06 06:58 PM
SIEGALL CLAY BSee RemarksFeb 08Option Exercise12.1620,148245,000740,690Feb 12 06:25 PM
SIEGALL CLAY BSee RemarksFeb 08Sale65.1720,1481,313,126732,613Feb 12 06:25 PM
GRYSKA DAVID WDirectorJan 08Option Exercise12.765,00063,80050,050Jan 10 09:09 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.1620,148245,000739,713Jan 10 08:27 PM
SIEGALL CLAY BPresident and CEOJan 08Sale65.7320,1481,324,237732,613Jan 10 08:27 PM
GRYSKA DAVID WDirectorJan 08Sale65.045,000325,20045,050Jan 10 09:09 PM
SIEGALL CLAY BPresident and CEODec 10Option Exercise12.1620,148245,000745,761Dec 12 07:31 PM
SIEGALL CLAY BPresident and CEODec 10Sale59.7420,1481,203,545732,613Dec 12 07:31 PM
HIMES VAUGHN BChief Technical OfficerNov 30Option Exercise12.005,00060,000177,329Dec 04 07:37 PM
HIMES VAUGHN BChief Technical OfficerNov 30Sale62.145,000310,718172,329Dec 04 07:37 PM
Cline Darren SEVP, CommercialNov 29Sale62.887,000440,16072,556Nov 30 06:32 PM
Cline Darren SEVP, CommercialNov 21Sale56.684,167236,20479,556Nov 21 06:42 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.1620,148245,000746,091Nov 09 05:54 PM
SIEGALL CLAY BPresident and CEONov 08Sale61.5420,1481,239,873732,613Nov 09 05:54 PM
AKKARAJU SRINIVASDirectorOct 30Option Exercise8.385,00041,90037,205Nov 01 05:55 PM
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.1620,148245,000746,550Oct 09 08:13 PM
SIEGALL CLAY BPresident and CEOOct 08Sale77.3920,1481,559,231732,613Oct 09 08:13 PM
SIEGALL CLAY BPresident and CEOSep 17Option Exercise12.1620,148245,000742,544Sep 19 06:36 PM
SIEGALL CLAY BPresident and CEOSep 17Sale76.8420,1481,548,196732,613Sep 19 06:36 PM
HIMES VAUGHN BChief Technical OfficerSep 07Option Exercise12.005,00060,000182,329Sep 11 07:26 PM
HIMES VAUGHN BChief Technical OfficerSep 07Sale76.995,000384,962177,329Sep 11 07:26 PM
SIMPSON TODD EChief Financial OfficerAug 27Sale74.235,427402,856173,565Aug 29 07:40 PM
SIEGALL CLAY BPresident and CEOAug 27Sale74.2325,5141,893,950636,632Aug 29 07:39 PM
LIU JEAN IGC/EVP, Leg AffairsAug 27Sale74.234,123306,05856,741Aug 29 07:37 PM
HIMES VAUGHN BChief Technical OfficerAug 27Sale74.235,530410,502159,376Aug 29 07:35 PM
Cline Darren SEVP, CommercialAug 27Sale74.234,784355,12565,079Aug 29 07:32 PM
SIEGALL CLAY BPresident and CEOAug 21Sale74.9525,0001,873,750662,146Aug 23 08:01 PM
SIEGALL CLAY BSee RemarksAug 09Option Exercise11.0918,831208,836703,857Aug 13 04:47 PM
SIEGALL CLAY BSee RemarksAug 09Sale72.7118,8311,369,153687,146Aug 13 04:47 PM
LIPPMAN MARC EDirectorJul 31Sale69.257,400512,450128,350Aug 02 08:00 PM
SIEGALL CLAY BPresident and CEOJul 09Option Exercise11.0918,832208,847702,356Jul 11 08:28 PM
SIEGALL CLAY BPresident and CEOJul 09Sale69.0718,8321,300,770687,146Jul 11 08:28 PM
Cline Darren SEVP, CommercialJun 12Option Exercise29.1410,086293,91079,831Jun 14 06:31 PM
Cline Darren SEVP, CommercialJun 12Sale69.0012,054831,68869,863Jun 14 06:31 PM
SIEGALL CLAY BPresident and CEOJun 08Option Exercise11.0918,832208,847705,278Jun 12 07:34 PM
SIEGALL CLAY BPresident and CEOJun 08Sale65.1218,8321,226,341687,146Jun 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.005,00060,000169,906Jun 04 07:11 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale58.475,000292,365164,906Jun 04 07:11 PM